By Colin Kenny, GP, Dromore
In this trial, 3297 participants with type 2 diabetes who were at high cardiovascuar (CV) risk were randomly assigned to receive once-weekly semaglutide or placebo for 104 weeks. The primary outcome was the first occurrence of CV death, non-fatal myocardial infarction or non-fatal stroke. In all, 2735 (83.0%) participants had established CVD, chronic kidney disease CKD or both at baseline.
The primary outcome occurred in 6.6% of participants in the semaglutide group and 8.9% of those in the placebo group. Non-fatal myocardial infarction occurred in 2.9% of individuals receiving semaglutide and 3.9% of those receiving placebo. Non-fatal stroke occurred in 1.6% and 2.7% of participants in the respective groups. The semaglutide group had lower rates of nephropathy and serious adverse events but higher rates of retinopathy and drug discontinuation due to adverse events.
To access the full publication, click here
